Literature DB >> 33583210

A GM1 gangliosidosis mutant mouse model exhibits activated microglia and disturbed autophagy.

Sichi Liu1, Yuyu Feng2, Yonglan Huang1, Xiaoling Jiang2, Chengfang Tang1, Fang Tang1, Chunhua Zeng2, Li Liu2.   

Abstract

GM1 gangliosidosis is a rare lysosomal storage disease caused by a deficiency of β-galactosidase due to mutations in the GLB1 gene. We established a C57BL/6 mouse model with Glb1G455R mutation using CRISPR/Cas9 genome editing. The β-galactosidase enzyme activity of Glb1G455R mice measured by fluorometric assay was negligible throughout the whole body. Mutant mice displayed no marked phenotype at eight weeks. After 16 weeks, GM1 ganglioside accumulation in the brain of mutant mice was observed by immunohistochemical staining. Meanwhile, a declining performance in behavioral tests was observed among mutant mice from 16 to 32 weeks. As the disease progressed, the neurological symptoms of mutant mice worsened, and they then succumbed to the disease by 47 weeks of age. We also observed microglia activation and proliferation in the cerebral cortex of mutant mice at 16 and 32 weeks. In these activated microglia, the level of autophagy regulator LC3 was up-regulated but the mRNA level of LC3 was normal. In conclusion, we developed a novel murine model that mimicked the chronic phenotype of human GM1. This Glb1G455R murine model is a practical in vivo model for studying the pathogenesis of GM1 gangliosidosis and exploring potential therapies.

Entities:  

Keywords:  GM1 gangliosidosis; microglia; mouse model; mutation

Mesh:

Substances:

Year:  2021        PMID: 33583210      PMCID: PMC8371306          DOI: 10.1177/1535370221993052

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  34 in total

Review 1.  Lysosomal Glycosphingolipid Storage Diseases.

Authors:  Bernadette Breiden; Konrad Sandhoff
Journal:  Annu Rev Biochem       Date:  2019-06-20       Impact factor: 23.643

2.  Therapeutic Benefit of Autophagy Modulation in Pompe Disease.

Authors:  Jeong-A Lim; Baodong Sun; Rosa Puertollano; Nina Raben
Journal:  Mol Ther       Date:  2018-05-03       Impact factor: 11.454

3.  Clinical and molecular characteristics of 11 Chinese probands with GM1 gangliosidosis.

Authors:  Yuyu Feng; Yonglan Huang; Xiaoyuan Zhao; Huiying Sheng; Yi Feng; Wen Zhang; Li Liu
Journal:  Metab Brain Dis       Date:  2018-09-28       Impact factor: 3.584

Review 4.  Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders.

Authors:  Kenneth J Valenzano; Richie Khanna; Allan C Powe; Robert Boyd; Gary Lee; John J Flanagan; Elfrida R Benjamin
Journal:  Assay Drug Dev Technol       Date:  2011-06       Impact factor: 1.738

5.  Impaired autophagy in microglia aggravates dopaminergic neurodegeneration by regulating NLRP3 inflammasome activation in experimental models of Parkinson's disease.

Authors:  Yue Qin; Jingru Qiu; Ping Wang; Jia Liu; Yong Zhao; Fan Jiang; Haiyan Lou
Journal:  Brain Behav Immun       Date:  2020-10-08       Impact factor: 7.217

Review 6.  Gene-Based Approaches to Inherited Neurometabolic Diseases.

Authors:  Valentina Poletti; Alessandra Biffi
Journal:  Hum Gene Ther       Date:  2019-09-10       Impact factor: 5.695

7.  Biomarkers of central nervous system inflammation in infantile and juvenile gangliosidoses.

Authors:  Jeanine R Jarnes Utz; Thomas Crutcher; Joseph Schneider; Patrick Sorgen; Chester B Whitley
Journal:  Mol Genet Metab       Date:  2014-12-06       Impact factor: 4.797

8.  Beta-galactosidase-deficient mouse as an animal model for GM1-gangliosidosis.

Authors:  J Matsuda; O Suzuki; A Oshima; A Ogura; Y Noguchi; Y Yamamoto; T Asano; K Takimoto; K Sukegawa; Y Suzuki; M Naiki
Journal:  Glycoconj J       Date:  1997-09       Impact factor: 2.916

9.  G(M1)-ganglioside degradation and biosynthesis in human and murine G(M1)-gangliosidosis.

Authors:  Renata Sano; Vera M T Trindade; Alessandra Tessitore; Alessandra d'Azzo; Matheus B Vieira; Roberto Giugliani; Janice C Coelho
Journal:  Clin Chim Acta       Date:  2005-01-26       Impact factor: 3.786

Review 10.  Pre-clinical Mouse Models of Neurodegenerative Lysosomal Storage Diseases.

Authors:  Jacob M Favret; Nadav I Weinstock; M Laura Feltri; Daesung Shin
Journal:  Front Mol Biosci       Date:  2020-04-15
View more
  3 in total

Review 1.  Gangliosides in nervous system development, regeneration, and pathologies.

Authors:  Juliana F Vasques; Renata Guedes de Jesus Gonçalves; Almir Jordão da Silva-Junior; Robertta Silva Martins; Fernanda Gubert; Rosalia Mendez-Otero
Journal:  Neural Regen Res       Date:  2023-01       Impact factor: 6.058

Review 2.  GM1 Gangliosidosis-A Mini-Review.

Authors:  Elena-Raluca Nicoli; Ida Annunziata; Alessandra d'Azzo; Frances M Platt; Cynthia J Tifft; Karolina M Stepien
Journal:  Front Genet       Date:  2021-09-03       Impact factor: 4.599

3.  Preclinical Enzyme Replacement Therapy with a Recombinant β-Galactosidase-Lectin Fusion for CNS Delivery and Treatment of GM1-Gangliosidosis.

Authors:  Jason Andrew Weesner; Ida Annunziata; Tianhong Yang; Walter Acosta; Elida Gomero; Huimin Hu; Diantha van de Vlekkert; Jorge Ayala; Xiaohui Qiu; Leigh Ellen Fremuth; David N Radin; Carole L Cramer; Alessandra d'Azzo
Journal:  Cells       Date:  2022-08-19       Impact factor: 7.666

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.